| Mrs Jacqueline Lowensteiner, CNS,APRN,BC | |
|
4 Spinello Ln, Chester, NJ 07930-2314 | |
| (908) 879-7733 | |
| (908) 879-7733 |
| Full Name | Mrs Jacqueline Lowensteiner |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 30 Years |
| Location | 4 Spinello Ln, Chester, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467524751 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 26NC05504500 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jacqueline A. Lowensteiner Llc | 6002946027 | 2 |
News Archive
The first members of WHO's international team arrived in Abidjan this week to support the Ministry of Health in dealing with an environmental health emergency caused by toxic waste.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
A collaborative team of scientists from the Uniformed Services University of the Health Sciences (USU) and the National Cancer Institute (NCI) have developed a novel strategy to inactivate highly virulent Venezuelan equine encephalitis virus (VEEV) that can infect and kill both animals and humans.
› Verified 5 days ago
| Entity Name | Jacqueline A. Lowensteiner Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053440586 PECOS PAC ID: 6002946027 Enrollment ID: O20100617000269 |
News Archive
The first members of WHO's international team arrived in Abidjan this week to support the Ministry of Health in dealing with an environmental health emergency caused by toxic waste.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
A collaborative team of scientists from the Uniformed Services University of the Health Sciences (USU) and the National Cancer Institute (NCI) have developed a novel strategy to inactivate highly virulent Venezuelan equine encephalitis virus (VEEV) that can infect and kill both animals and humans.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jacqueline Lowensteiner, CNS,APRN,BC 4 Spinello Ln, Chester, NJ 07930-2314 Ph: (908) 879-7733 | Mrs Jacqueline Lowensteiner, CNS,APRN,BC 4 Spinello Ln, Chester, NJ 07930-2314 Ph: (908) 879-7733 |
News Archive
The first members of WHO's international team arrived in Abidjan this week to support the Ministry of Health in dealing with an environmental health emergency caused by toxic waste.
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
Vertex Pharmaceuticals Incorporated announced today a correction to the previously reported responder analysis, as well as additional data from, the recent interim analysis of an ongoing Phase 2 study of VX-809 and KALYDECO that showed significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
A collaborative team of scientists from the Uniformed Services University of the Health Sciences (USU) and the National Cancer Institute (NCI) have developed a novel strategy to inactivate highly virulent Venezuelan equine encephalitis virus (VEEV) that can infect and kill both animals and humans.
› Verified 5 days ago